Immorta Bio's SenoVax™ Shows Promise in CTE with Preclinical Findings

Immorta Bio Unveils Promising Data on Senolytic Immunotherapy SenoVax™

Immorta Bio, Inc., renowned for its innovative approach towards longevity and age-related diseases, has recently announced groundbreaking preclinical findings regarding its senolytic immunotherapy, SenoVax™. This new data suggests that SenoVax™ could improve conditions of Chronic Traumatic Encephalopathy (CTE), a serious neurodegenerative ailment primarily associated with repeated head trauma.

On September 24, 2025, the Miami-based company revealed that it has filed a U.S. patent application containing these unexpected results from their research. CTE often plagues athletes and military veterans, leading to profound changes in mood, behavior, and cognitive function, potentially culminating in dementia. Unfortunately, there are currently no approved treatments that can modify the progression of this devastating disease.

Dr. Thomas E. Ichim, President and Chief Scientific Officer of Immorta Bio, emphasized the significance of these findings, stating, "Our data suggest that cellular senescence is a driver of CTE-related inflammation and brain injury." This indicates a promising potential for senolytic therapies to address inflammatory and damaging signals related to CTE.

The efficacy of SenoVax™ stands out among the range of senolytics tested, showcasing its unique capability to generate antibodies that effectively counteract the markers associated with CTE. Unlike traditional approaches that target symptomatic relief, SenoVax™ is designed to harness the body's immune system to eliminate senescent cells, often referred to as 'zombie' cells, which are known to contribute to cancer progression and age-related ailments. In addition to its focus on CTE, SenoVax™ has shown a remarkable ability to control tumors in various cancers, including lung, breast, and pancreatic cancers.

Immorta Bio has also taken significant steps towards clinical evaluation, having submitted an Investigational New Drug (IND) application to start trials for advanced non-small cell lung cancer (NSCLC). In collaboration with the FDA, they are preparing for a Good Manufacturing Practices (GMP) demonstration run, which is the final hurdle prior to IND clearance.

Dr. Boris N. Reznik, Chairman and CEO of Immorta Bio, expressed his enthusiasm, noting the potential crossover applications of SenoVax™. He stated, "Seeing our cancer immunotherapy show promise in a neurologic, trauma-linked disease underscores how longevity science can unlock cross-disciplinary therapies."

Immorta Bio is committed to not only advancing its lung cancer trial but also exploring the implications of SenoVax™ for CTE and other neurodegenerative diseases in a systematic manner.

This exciting development underscores a vital intersection in the fields of cancer therapy and neuroscience, potentially revolutionizing the treatment landscape for both diseases. With continued research and the promise of SenoVax™, the medical community may soon witness new innovative methods of combating CTE and enhancing patient outcomes.

About Immorta Bio
Immorta Bio, Inc. is dedicated to pioneering advancements in longevity-focused biotechnology, with a goal of utilizing personalized cellular and immune therapies. Among their innovative products is SenoVax™, a cutting-edge senolytic immunotherapy that aims to rejuvenate cells and combat age-related diseases. For more information about Immorta Bio and its other developments like StemCellRevivify™, please visit immortabio.com.

Media Contact:
Immorta Bio, Inc.
Phone: +1 (305) 632-2939
Email: [email protected]

This overview of Immorta Bio's latest findings highlights a universal concern regarding memory and cognitive decline associated with aging and trauma. As they continue to uncover the mechanisms behind these diseases, there is hope that effective treatments will soon be on the horizon.